Abstracts tagged "Clinical research"

Abstract Number: 094 • 2023 Pediatric Rheumatology Symposium
Provider Assessment of the Temporomandibular Joint in Juvenile Idiopathic Arthritis
Anna Costello¹, Marinka Twilt² and Melissa Lerman¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: TM joint arthritis is an underrecognized complication of JIA that can cause long-term problems including decreased mandibular growth, altered facial morphology, and orofacial pain.…
Abstract Number: 106 • 2020 Pediatric Rheumatology Symposium
Childhood-onset Takayasu Arteritis: A Single Center Case Series of Atypical and Varied Presentations
Uptej Khalsa¹ and Imelda Balboni ¹, ¹Stanford University, Palo Alto, California
Background/Purpose: Childhood-onset Takayasu arteritis is a rare inflammatory vessel disease that predominantly affects the aorta and its major branches. Clinical presentation at disease onset can…
Abstract Number: 469 • 2019 ACR/ARP Annual Meeting
Location and Size of Affected Joints Are Useful to Predict Prognosis of Patients with Rheumatoid Arthritis
Susumu Nishiyama¹, Tetsuji Sawada ² and Shigeto Tohma ³, ¹Rheumatic Disease Center, Kurashiki Medical Center, Kurashiki, Japan, ²Department of Rheumatology, Tokyo Medical University Hospital, Tokyo, Japan, ³National Hospital Organization Tokyo National Hospital, Tokyo, Japan
Background/Purpose: To predict prognosis of patients with rheumatoid arthritis (RA) from the location and the size of affected joints.Methods: Data of 7,776 patients with RA,…
Abstract Number: 638 • 2019 ACR/ARP Annual Meeting
Longitudinal Trends for Estimated Glomerular Filtration Rate and Predictors of Change in Patients with Systemic Lupus Erythematosus
Terry Cheuk Fung Yip ¹, Michelle Petri ² and Laurence Magder³, ¹Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: To characterize the longitudinal trajectory of estimated glomerular filtration rate (eGFR) in patients with systemic lupus erythematosus (SLE) and identify predictors of change in…
Abstract Number: 673 • 2019 ACR/ARP Annual Meeting
Clinical Characteristics of Lymphadenopathy in Systemic Lupus Erythematous: A Case Control Study from a Tertiary Care Center
Elizabeth Graef¹, Daniel Magliulo ¹, Norris Hollie ¹, Chelsea Marcus ² and Vasileios Kyttaris ³, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: While lymphadenopathy and/or lymphadenitis (LAD) is considered a relatively common clinical finding in SLE patients, its clinical significance is poorly understood. Previous studies described…
Abstract Number: 739 • 2019 ACR/ARP Annual Meeting
Does Digital Thermal Monitoring Correlate to Specific Nailfold Videocapillaroscopy Abnormalities?
Mislav Radic¹, Rebecca Overbury ² and Tracy Frech ³, ¹University Hospital Split, Split, Croatia, ²University of Utah, Departments of Pediatrics and Internal Medicine, Division of Rheumatology, Salt Lake City, UT, ³Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT
Background/Purpose: The fingers have specialized structural and functional features for thermoregulation, and are the most common areas of Raynaud’s phenomenon (RP) in systemic sclerosis (SSc).…
Abstract Number: 1308 • 2019 ACR/ARP Annual Meeting
Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes
Sarah Kennedy ¹, Chris Swearingen ¹, Jeyanesh Tambiah¹, Daniel Clauw ² and Philip G Conaghan ³, ¹Samumed, LLC, San Diego, ²Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Patient-reported outcomes (PROs) in knee osteoarthritis (OA) trials have been difficult to accurately measure due to heterogenous sources of pain (e.g., from comorbid conditions…
Abstract Number: 1329 • 2019 ACR/ARP Annual Meeting
Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis
Kevin Winthrop¹, Mark Genovese ², Bernard Combe ³, Yoshiya Tanaka ⁴, Alan Kivitz ⁵, Franziska Matzkies ⁶, Beatrix Bartok ⁶, Lei Ye ⁶, Ying Guo ⁶, Chantal Tasset ⁷, John Sundy ⁶, Edward Keystone ⁸, Rene Westhovens ⁹, William F.C. Rigby ¹⁰ and Gerd Burmester ¹¹, ¹Oregon Health and Science University, Portland, OR, ²Stanford University, Stanford, CA, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Galapagos NV, Mechelen, Belgium, ⁸Mount Sinai Hospital and University of Toronto, Toronto, Canada, ⁹University Hospitals, Leuven, Belgium, ¹⁰Dartmouth College, Lebanon, NH, ¹¹Charité—University Medicine Berlin, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is an orally administered, selective inhibitor of Janus Kinase 1 (JAK1) that is under development for the treatment of RA and other…
Abstract Number: 1379 • 2019 ACR/ARP Annual Meeting
Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Roy Fleischmann¹, Carlo Selmi ², Miguel Angel González-Gay ³, Hubert van Hoogstraten ⁴, Owen Hagino ⁴, Tejasweeni Rajput ⁵, Gregory St John ⁶, Frank Buttgereit ⁷ and Mark Genovese ⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Humanitas Research Hospital, University of Milan, Milan, Italy, ³Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Sanofi, Bridgewater, NJ, ⁵Cytel, Mumbai, India, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Stanford University, Stanford, CA
Background/Purpose: EXTEND (NCT01146652) is a long-term, open-label extension (OLE) study of sarilumab for the treatment of RA. This post hoc analysis assessed changes in oral…
Abstract Number: 1802 • 2019 ACR/ARP Annual Meeting
Utility of Repeat Latent Tuberculosis Testing in Patients Taking Biologics
Urmi Khanna¹, Ariana Ellis ², AbdulAziz Galadari ³, Jeffery Hu ⁴, Josh Gallop ⁵, M. Elaine Husni ⁶ and Anthony Fernandez ⁷, ¹Department of Dermatology , Cleveland Clinic, Cleveland, OH, ²Northeast Ohio Medical University, Cleveland, OH, ³Cleveland Clinic, Abu Dhabi, Cleveland, ⁴Case Western Reserve University, Cleveland, ⁵Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ⁶Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷Department of Dermatology and Pathology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Guidelines for repeat Latent Tuberculosis Infection (LTBI) testing while on biologics are not clearly defined. The American College of Rheumatology recommends repeat LTBI screening…
Abstract Number: 2197 • 2019 ACR/ARP Annual Meeting
Clinically Relevant Improvements in Knee Osteoarthritis Pain with Diclofenac Sodium Gel 1%
Marc C. Hochberg¹, Bharat Patel ², Sandy Yacoub Garas ³ and Roy Altman ⁴, ¹University of Maryland School of Medicine, Baltimore, MD, ²GlaxoSmithKline Consumer Healthcare, Weybridge, United Kingdom, ³GlaxoSmithKline Consumer Healthcare, Warren, NJ, ⁴University of California, Los Angeles
Background/Purpose: Topical agents are recommended for the initial treatment of patients with knee osteoarthritis (OA). Diclofenac sodium gel 1% (DSG 1%), a topical nonsteroidal anti-inflammatory…
Abstract Number: 2385 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Chinese Herbal Medicine Biqi Capsule Combined with Methotrexate in Patients with Rheumatoid Arthritis: A Pilot Study
Runyue Huang¹, Qingchun Huang ², Jiaqi Wu ³, Xiao Cai ⁴, Xiumin Chen ⁴, Yue Zhao ⁴, Yongliang Chu ², Jianyong Zhang ⁵, Jianhong Peng ⁶, Zhisheng Huang ⁷, Xianghong Chen ², Zehao Liu ⁸ and Aihua Ou ², ¹The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China; Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China;, Guangzou, Guangdong, China (People's Republic), ²The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China (People's Republic), ³Section Rheumatology Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzou, China (People's Republic), ⁴The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzou, China (People's Republic), ⁵Shenzhen Hospital of Traditional Chinese Medicine, Shenzhen, China (People's Republic), ⁶Dongguan Hospital of Traditional Chinese Medicine, Dongguan, China (People's Republic), ⁷Guangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Huandu, China (People's Republic), ⁸Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China (People's Republic)
Background/Purpose: In recent years, the combination therapies of conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) with Chinses medicine has prevailed for the treatment of rheumatoid arthritis…
Abstract Number: 2841 • 2019 ACR/ARP Annual Meeting
A Double-Blind, Placebo-Controlled, Phase 2 Trial of a Novel Toll-Like Receptor 7/8/9 Antagonist (IMO-8400) in Dermatomyositis
Yoo Jung Kim¹, Elena Schiopu ², Katalin Dankó ³, Tahseen Mozaffar ⁴, Srinivas Chunduru ⁵, Kirstin Lees ⁶, Namita Goyal ⁴, David Fiorentino ⁷ and Kavita Sarin ⁷, ¹Stanford University School of Medicine, Redwood City, CA, ²Department of Rheumatology, University of Michigan, Ann Arbor, ³Department of Clinical Immunology, Medical Faculty, University of Debrecen, Debrecen, Hungary, ⁴Department of Neurology, University of California Irvine, Irvine, CA, ⁵Idera Pharmaceuticals, Inc., Cambridge, MA, ⁶Idera Pharmaceuticals, Inc., Cambridge, ⁷Department of Dermatology, Stanford University School of Medicine, Redwood City, CA
Background/Purpose: Dermatomyositis (DM) is a rare inflammatory disease of skin and muscle associated with characteristic skin findings, muscle weakness, interstitial lung disease, pruritus, and malignancies.…
Abstract Number: 2847 • 2019 ACR/ARP Annual Meeting
Testing Different Thresholds for Patient Global Assessment in Defining ACR-EULAR Boolean Remission Criteria for RA
Paul Studenic¹, David Felson ², Maarten de Wit ³, Farideh Alasti ⁴, Tanja Stamm ¹, Josef Smolen ¹ and Daniel Aletaha ¹, ¹Medical University of Vienna, Vienna, Austria, ²Boston University School of Medicine, Department of Rheumatology, Boston, ³Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁴Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria
Background/Purpose: The patient global assessment (PGA) is a core set variable to assess RA disease activity. It is strongly linked to patient-reported pain and is…
Abstract Number: L07 • 2018 ACR/ARHP Annual Meeting
VIB4920, a Novel, Engineered CD40L Antagonist Decreased Disease Activity and Improved Biomarkers of Immune Activation in Patients with Active Rheumatoid Arthritis in a Phase 1b, Multiple-Ascending Dose Proof-of-Concept Study
Marius Albulescu¹, Ulf Müller-Ladner², Rachel Moate³, Kate Middleton³, Liangwei Wang⁴, Jorn Drappa⁴ and Gabor Illei⁵, ¹Clinical Development, MedImmune, Cambridge, UK, Cambridge, United Kingdom, ²Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Germany, Bad Nauheim, Germany, ³MedImmune, Cambridge, UK, Cambridge, United Kingdom, ⁴Viela Bio, Gaithersburg, USA, Gaithersburg, MD, ⁵Viela Bio, Gaithersburg, USA, Gaithersberg, MD
Background/Purpose: The CD40L/CD40 co-stimulatory pathway is important for T-cell-dependent antibody production and plays a central role in RA and other autoimmune diseases. VIB4920 (formerly MEDI4920)…

1
2
3
…
7
Next Page »